Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Addex Therapeutics
Deal Size : $2.5 million
Deal Type : Financing
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine
Details : Stalicla will use the financing to advance its portfolio of autism focused drug candidates, including STP1, a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).
Product Name : STP1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2025
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Addex Therapeutics
Deal Size : $2.5 million
Deal Type : Financing
Vandria Doses Subjects in First-In-Human Trial of VNA-318 Mitophagy Inducer
Details : VNA-318 is an orally available first-in-class mitophagy inducer, small molecule. It is being evaluated to treat cognitive impairment, dementia, Alzheimer’s, and Parkinson’s Disease.
Product Name : VNA-318
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2024
Anokion Supports ANK-700 as Potential Treatment for Relapsing-Remitting MS
Details : Anokion's ANK-700 is being assessed as a potential disease-modifying treatment for patients with relapsing-remitting multiple sclerosis.
Product Name : ANK-700
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : SPRIM Global Investments
Deal Size : $17.4 million
Deal Type : Series B Financing
Stalicla Secures $17.4 Million Series B Financing for Precision Neuro Advancements
Details : Proceeds will support Stalicla's phase 2 Autism Spectrum Disorder (ASD) trial for STP1, a fixed-dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).
Product Name : STP1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : SPRIM Global Investments
Deal Size : $17.4 million
Deal Type : Series B Financing
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Firefly Neuroscience
Deal Size : Undisclosed
Deal Type : Partnership
Details : STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candi...
Product Name : STP1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Firefly Neuroscience
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.
Product Name : ASN90
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In addition to showing good safety and tolerability profile, and dose-dependent target engagement, STP1 treatment resulted in positive signals in clinical markers of neurological and behavioral function, including improved processing speed and crystalliz...
Product Name : STP1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2022
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences
Details : ASN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathic disease, progressive supranuclear palsy (PSP), and was granted Orphan Drug Designation by the US FDA for the treatment of Progressive Supranuclear Palsy (PSP).
Product Name : ASN120290
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2021
Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis
Details : The MoveS-it Study (Multiple Sclerosis Study of ANK-700 to Assess Safety and Immune Tolerance) is a randomized, double-blind, placebo-controlled, first-in-human study designed to evaluate the safety and tolerability of single and multiple ascending doses...
Product Name : ANK-700
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.
Product Name : STP1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable